Caren Pharma
Caren Pharma develops hormone-based therapeutics for age-related diseases, aiming to translate validated biology into longevity therapeutics. Their mission is to create next-generation treatments that address neurodegeneration and chronic conditions associated with aging, with a focus on safety, precision, and long-term impact.
Industries
Nr. of Employees
small (1-50)
Products
CP001M
Development program targeting Alzheimer's disease (male population) focused on cognitive function and disease pathology modulation.
CP002F
Development program targeting Alzheimer's disease (female population) aimed at cognitive outcomes and disease pathology.
CP003
Development program targeting Parkinson's disease.
Additional pipeline programs (CP004–CP011)
Programs listed targeting breast cancer, prostate cancer, metabolic syndrome, COPD, multiple sclerosis, osteoporosis, adult depression, and sleep apnea; intended for development via the same reformulation and streamlined pathway.
CP001M
Development program targeting Alzheimer's disease (male population) focused on cognitive function and disease pathology modulation.
CP002F
Development program targeting Alzheimer's disease (female population) aimed at cognitive outcomes and disease pathology.
CP003
Development program targeting Parkinson's disease.
Additional pipeline programs (CP004–CP011)
Programs listed targeting breast cancer, prostate cancer, metabolic syndrome, COPD, multiple sclerosis, osteoporosis, adult depression, and sleep apnea; intended for development via the same reformulation and streamlined pathway.
Services
Development and optimization of pharmaceutical formulations derived from clinically validated hormone agents; preparing reformulations intended for clinical evaluation.
Design and execution of preclinical dosing, efficacy, behavioral, and neuropathology studies in neurodegeneration models.
Design of streamlined clinical development programs and regulatory planning intended to accelerate clinical translation of reformulated therapeutics.
Engagement with strategic partners including development networks, contract organizations, and academic advisors to support program execution.
Development and optimization of pharmaceutical formulations derived from clinically validated hormone agents; preparing reformulations intended for clinical evaluation.
Design and execution of preclinical dosing, efficacy, behavioral, and neuropathology studies in neurodegeneration models.
Design of streamlined clinical development programs and regulatory planning intended to accelerate clinical translation of reformulated therapeutics.
Engagement with strategic partners including development networks, contract organizations, and academic advisors to support program execution.
Expertise Areas
- Hormone-based therapeutics
- Drug repurposing and reformulation
- Preclinical neuroscience and behavioral pharmacology
- Neuropathology and biomarker assessment (amyloid/tau)
Key Technologies
- Animal models of neurodegeneration
- Behavioral cognitive assays (e.g., maze tests)
- Immunohistochemistry / quantitative neuropathology
- Pharmaceutical formulation and reformulation methods
News & Updates
Achieved a new intellectual property milestone in September 2024.
Completed a proof-of-concept study in August 2024.
Achieved a new intellectual property milestone in September 2024.
Completed a proof-of-concept study in August 2024.